𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High incidence of thromboembolism in patients with central nervous system lymphoma

✍ Scribed by Neta Goldschmidt; Eduard Linetsky; Edna Shalom; David Varon; Tali Siegal

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
60 KB
Volume
98
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

Venous thromboembolism (VTE) is a frequent complication in patients with cancer throughout the course of the disease. Patients with brain tumors are at particularly high risk for VTE, and several risk factors were found in patients with malignant glioma. To the authors' knowledge, the incidence of VTE in patients with central nervous system (CNS) lymphoma is not known, and possible risk factors have not been identified to date. The objective of this study was to evaluate the frequency and risk factors of VTE in patients with CNS lymphoma.

METHODS

The authors retrospectively evaluated the medical records of 42 patients with CNS lymphoma who were treated at their center between 1992 and 2001.

RESULTS

It was found that 25 patients (59.5%) had VTE, and, in 3 patients (7%), the VTE was fatal. The authors could not demonstrate that age or ambulatory status could predict VTE in this group of patients, but almost all VTE events occurred during the early period of intensive therapy.

CONCLUSIONS

The high incidence of VTE found in this study indicates that anticoagulant prophylaxis with low‐molecular‐weight heparin probably outweighs the risk and cost of such therapy. A prospective evaluation of newly diagnosed patients with CNS lymphoma is underway at the authors' center. Cancer 2003;98:1239–42. Β© 2003 American Cancer Society.

DOI 10.1002/cncr.11623

πŸ“œ SIMILAR VOLUMES

Decreasing incidence rates of primary ce
Decreasing incidence rates of primary central nervous system lymphoma
✍ Nina S. Kadan-Lottick; Maria C. Skluzacek; James G. Gurney πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 187 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Incidence rates of primary central nervous system lymphomas (PCNSL) in the U.S. were reported to have increased dramatically during the 1980s and early 1990s. Recent reports portray a continuation of this trend. With potential etiologic factors related to immunosuppressio

Central nervous system dissemination in
Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options
✍ AndrΓ©s J. M. Ferreri; Andrea Assanelli; Roberto Crocchiolo; Fabio Ciceri πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 150 KB

## Abstract Central nervous system (CNS) dissemination is a rare (4–5%) but usually fatal complication of aggressive lymphomas. Prophylaxis modalities to prevent CNS dissemination in aggressive lymphomas cannot be widely applied to every lymphoma patient since it is associated with increased risk o

Primary central nervous system lymphoma
Primary central nervous system lymphoma in a patient treated with natalizumab
✍ Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 3 views

## Abstract A 40‐year‐old man with relapsing‐remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th deca